A detailed history of O'Shaughnessy Asset Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, O'Shaughnessy Asset Management, LLC holds 12,067 shares of HALO stock, worth $619,037. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,067
Previous 11,531 4.65%
Holding current value
$619,037
Previous $426,000 15.02%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $18,052 - $22,485
536 Added 4.65%
12,067 $490,000
Q4 2023

Feb 09, 2024

BUY
$33.32 - $42.1 $112,488 - $142,129
3,376 Added 41.4%
11,531 $426,000
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $47,762 - $57,679
1,310 Added 19.14%
8,155 $311,000
Q2 2023

Aug 11, 2023

SELL
$30.28 - $38.74 $14,716 - $18,827
-486 Reduced 6.63%
6,845 $246,000
Q1 2023

May 12, 2023

SELL
$32.86 - $55.7 $20,701 - $35,091
-630 Reduced 7.91%
7,331 $279,000
Q4 2022

Feb 10, 2023

SELL
$40.06 - $59.44 $166,329 - $246,794
-4,152 Reduced 34.28%
7,961 $452,000
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $44,925 - $60,375
1,166 Added 10.65%
12,113 $479,000
Q2 2022

Aug 11, 2022

BUY
$37.35 - $48.3 $24,464 - $31,636
655 Added 6.36%
10,947 $482,000
Q1 2022

May 13, 2022

BUY
$31.97 - $41.06 $607 - $780
19 Added 0.18%
10,292 $410,000
Q4 2021

Feb 11, 2022

BUY
$31.82 - $40.75 $954 - $1,222
30 Added 0.29%
10,273 $413,000
Q3 2021

Nov 10, 2021

BUY
$38.47 - $46.42 $66,937 - $80,770
1,740 Added 20.46%
10,243 $418,000
Q2 2021

Aug 09, 2021

SELL
$38.84 - $51.31 $310 - $410
-8 Reduced 0.09%
8,503 $386,000
Q1 2021

May 14, 2021

SELL
$39.51 - $51.45 $1,975 - $2,572
-50 Reduced 0.58%
8,511 $355,000
Q4 2020

Feb 11, 2021

BUY
$25.81 - $43.62 $220,314 - $372,340
8,536 Added 34144.0%
8,561 $366,000
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $406 - $670
25 New
25 $1,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.15B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track O'Shaughnessy Asset Management, LLC Portfolio

Follow O'Shaughnessy Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Shaughnessy Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on O'Shaughnessy Asset Management, LLC with notifications on news.